Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus

被引：30

作者：

Deng, Jianghong ^{[1
,2
]}

Chalhoub, Nathalie E. ^{[3
]}

Sherwin, Catherine M. ^{[4
]}

Li, Caifeng ^{[1
]}

Brunner, Hermine I. ^{[2
]}

机构：

[1] Capital Med Univ, Natl Ctr Childrens Hlth, Beijing Childrens Hosp, Dept Rheumatol, 56 Nanlishi Rd, Beijing 100045, Peoples R China

[2] Cincinnati Childrens Hosp Med Ctr, Div Rheumatol, MLC 4010,3333 Burnet Ave, Cincinnati, OH 45229 USA

[3] Univ Cincinnati, Coll Med, Div Immunol Allergy & Rheumatol, Cincinnati, OH USA

[4] Univ Utah, Sch Med, Dept Pediat, Div Clin Pharmacol, Salt Lake City, UT USA

来源：

SEMINARS IN ARTHRITIS AND RHEUMATISM | 2019年 / 49卷 / 02期

关键词：

Glucocorticoids; Pharmacokinetics; Pharmacodynamics; Childhood-onset systemic lupus erythematosus; EVIDENCE-BASED RECOMMENDATIONS; GROWTH-HORMONE-SECRETION; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; METHYLPREDNISOLONE PHARMACOKINETICS; PEDIATRIC RHEUMATOLOGY; DISEASE-ACTIVITY; DAMAGE; PREDNISOLONE; THERAPY; PHARMACODYNAMICS;

D O I：

10.1016/j.semarthrit.2019.03.010

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Glucocorticoids are potent anti-inflammatory and immunosuppressant medications and remain the mainstay of systemic lupus erythematosus (SLE) therapy. The potency of a specific glucocorticoid, i.e., the dose of glucocorticoid that is required to produce a specific effect, is dependent on its pharmacokinetic (PK) and pharmacodynamic (PD) properties. In this review, we summarize the PK/PD properties of commonly used glucocorticoids in an attempt to better delineate their role in the management of children with childhood onset SLE (cSLE). We also address glucocorticoid side effects as these play a major role when deciding on the dose, frequency, and duration of use. A better understanding of the pharmacology of glucocorticoids appears useful to achieve improved outcomes in the management of cSLE. (C) 2019 Elsevier Inc. All rights reserved.

引用

页码：251 / 259

页数：9

共 50 条

[1] Cost of treatment of childhood-onset systemic lupus erythematosus
Brunner, HI
Sherrard, TM
Klein-Gitelman, MS
[J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2006, 55 (02): : 184 - 188
[2] Childhood-onset systemic lupus erythematosus
Olowu, Wasiu
[J]. JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2007, 99 (07) : 777 - 784
[3] Childhood-Onset Systemic Lupus Erythematosus
Sura, Anjali
Failing, Christopher
Co, Dominic O.
Syverson, Grant
[J]. PEDIATRICS IN REVIEW, 2024, 45 (06) : 316 - 328
[4] Childhood-onset systemic lupus erythematosus
Bader-Meunier, B
Quartier, P
Deschenes, G
Cochat, P
Haddad, E
Koné-Paut, I
Leblanc, T
Prieur, AM
Salomon, R
Bodemer, C
Lévy, M
[J]. ARCHIVES DE PEDIATRIE, 2003, 10 (02): : 147 - 157
[5] Update on the pathogenesis and treatment of childhood-onset systemic lupus erythematosus
Couture, Julie
Silverman, Earl D.
[J]. CURRENT OPINION IN RHEUMATOLOGY, 2016, 28 (05) : 488 - 496
[6] Cost of treatment of childhood-onset systemic lupus erythematosus (cSLE).
Brunner, HI
Sherrard, TM
Klein-Gitelman, MS
[J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S533 - S533
[7] LUPUS HEADACHES IN THE CHILDHOOD-ONSET OF SYSTEMIC LUPUS ERYTHEMATOSUS
Moradinejad, Mohammad Hassan
Zamani, Gholamreza
[J]. RHEUMATOLOGY, 2012, 51 : I22 - I22
[8] Childhood-onset bullous systemic lupus erythematosus
Lourenco, D. M. R.
Gomes, R. Cunha
Aikawa, N. E.
Campos, L. M. A.
Romiti, R.
Silva, C. A.
[J]. LUPUS, 2014, 23 (13) : 1422 - 1425
[9] Childhood-onset systemic lupus erythematosus: an update
Borgia, Roberto Ezequiel
Silverman, Earl D.
[J]. CURRENT OPINION IN RHEUMATOLOGY, 2015, 27 (05) : 483 - 492
[10] Biomarkers in Childhood-Onset Systemic Lupus Erythematosus
Cody, Ellen M.
Brunner, Hermine, I
[J]. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2022, 48 (01) : 271 - 285

← 1 2 3 4 5 →